CN110662532A - 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs) - Google Patents

用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs) Download PDF

Info

Publication number
CN110662532A
CN110662532A CN201880034533.8A CN201880034533A CN110662532A CN 110662532 A CN110662532 A CN 110662532A CN 201880034533 A CN201880034533 A CN 201880034533A CN 110662532 A CN110662532 A CN 110662532A
Authority
CN
China
Prior art keywords
drug delivery
delivery vehicle
nanoscale drug
nanoscale
dnv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880034533.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·约翰
西村一郎
N·苏比阿
J·卡姆帕格纳
P·R·斯皮尔曼
M·P·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CN110662532A publication Critical patent/CN110662532A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880034533.8A 2017-04-03 2018-04-02 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs) Pending CN110662532A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480924P 2017-04-03 2017-04-03
US62/480,924 2017-04-03
PCT/US2018/025749 WO2018187240A1 (en) 2017-04-03 2018-04-02 Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery

Publications (1)

Publication Number Publication Date
CN110662532A true CN110662532A (zh) 2020-01-07

Family

ID=63712640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034533.8A Pending CN110662532A (zh) 2017-04-03 2018-04-02 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)

Country Status (6)

Country Link
US (1) US12514929B2 (https=)
EP (1) EP3606557A4 (https=)
JP (2) JP7280624B2 (https=)
CN (1) CN110662532A (https=)
CA (1) CA3058782A1 (https=)
WO (1) WO2018187240A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114259486A (zh) * 2020-09-16 2022-04-01 香港科技大学 木犀草素及其药物组合物的应用
WO2023226136A1 (zh) * 2022-05-26 2023-11-30 深圳先进技术研究院 一种用于脑部疾病诊断和治疗的微针系统及其制备方法
CN117551095A (zh) * 2023-11-09 2024-02-13 中国药科大学 一种玫瑰树碱衍生物及其制备方法与应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2018187240A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN110251508A (zh) * 2019-05-07 2019-09-20 苏州大学 Nsc-156529作为t-型钙通道拮抗剂的应用
WO2021207273A1 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics
CN111569061A (zh) * 2020-05-06 2020-08-25 吴延恒 一种用于核酸疫苗增强剂的纳米材料
CN113975397B (zh) * 2021-10-26 2023-08-22 中南大学湘雅三医院 一种基因/小分子化合物纳米递药系统及其制备方法与应用
CN116392449A (zh) * 2023-04-28 2023-07-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 一种橘红素纳米脂质体冻干制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1951368A (zh) * 2006-11-03 2007-04-25 李万忠 白藜芦醇口服多相脂质体及其制备方法
CN103446055A (zh) * 2013-08-22 2013-12-18 合肥工业大学 三羟基异黄酮脂质纳米体的制备方法
CN105287382A (zh) * 2015-12-10 2016-02-03 南昌大学 叶酸-壳聚糖修饰姜黄素纳米脂质体的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
FR2658418B1 (fr) 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
FR2699818B1 (fr) * 1992-12-24 1995-02-03 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
WO2000024377A1 (en) * 1998-10-23 2000-05-04 Idea Innovative Dermale Applikationen Gmbh Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
AU2003273977B2 (en) 2002-10-11 2007-07-12 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CN1285383C (zh) 2004-07-22 2006-11-22 周翔 亲水亲脂自封闭小体液相核心空化成囊泡的方法及应用
GB0416861D0 (en) 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2009009115A2 (en) 2007-07-11 2009-01-15 Nevsky Pharmaceutical Development Liposome compositions for treatment of hepatitis c
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009087568A2 (en) * 2008-01-10 2009-07-16 Universidade De Coimbra Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties
CN101474155B (zh) 2009-01-24 2011-03-16 重庆医科大学 注射用肺靶向载药前体脂质体及其使用方法
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
SG174287A1 (en) 2009-03-09 2011-10-28 Univ California Single protein nanocapsules for protein delivery with long-term effect
US20110178456A1 (en) 2009-04-03 2011-07-21 The Regents Of The University Of California Assisting transdermal drug delivery by means of tissue freezing, vacuum pressure and photoheating procedures
CN101874763A (zh) 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
AU2010268726A1 (en) * 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
EP2394640A1 (en) * 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
NZ605874A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
US10357575B2 (en) 2010-09-24 2019-07-23 Case Western Reserve University Stabilized nanobubbles for diagnostic and therapeutic applications
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
EP2678007A4 (en) 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION
GB2503845A (en) * 2011-03-21 2014-01-08 Gregor Cevc Optimised preparations of highly adaptable aggregates
CA2846611A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2013059617A1 (en) 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
WO2013066903A1 (en) 2011-10-31 2013-05-10 Mallinckrodt Llc Combinational liposome compositions for cancer therapy
WO2014015027A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
AU2013302526B2 (en) 2012-08-15 2018-03-22 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
US9943482B2 (en) 2013-02-26 2018-04-17 University Of Louisville Research Foundation, Inc. Milk-derived microvesicle compositions and related methods
WO2015058148A1 (en) 2013-10-17 2015-04-23 Children's Hospital Los Angeles Antibody dependent exosome therapy
US9987227B2 (en) 2013-10-22 2018-06-05 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
US20150320706A1 (en) * 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CA2997811C (en) 2015-10-01 2021-09-21 University Of Ottawa Exosome packaging of nucleic acids
HK1257801A1 (zh) * 2015-10-28 2019-11-01 宾夕法尼亚州大学信托人 用於基因治疗的腺伴随病毒载体的鞘内给药
WO2017087685A1 (en) * 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
US20190112351A1 (en) 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
US20180028600A1 (en) 2016-07-15 2018-02-01 Korea Institute Of Science And Technology Novel recombinant exosome and use thereof
CN106389137B (zh) 2016-08-29 2019-07-16 杭州素妍化妆品有限公司 一种亚麻籽油脂质体及其制备与应用
US20180067121A1 (en) 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome
EP3554638B1 (en) 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
KR102036051B1 (ko) 2017-02-15 2019-10-24 고려대학교 세종산학협력단 엑소좀 기반의 나노입자 복합체 및 이의 제조방법
WO2018187240A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US11344627B2 (en) 2017-06-27 2022-05-31 Wisconsin Alumni Research Foundation Dendrimer-exosome hybrid nanoparticles as a delivery platform
WO2019094679A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of California BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
AU2018367670A1 (en) 2017-11-17 2020-05-07 Lonza Sales Ag Compositions of engineered exosomes and methods of loading luminal exosomes payloads
WO2019203706A1 (en) 2018-04-20 2019-10-24 Telefonaktiebolaget Lm Ericsson (Publ) Information decoder for polar codes
CA3092162A1 (en) 2018-04-25 2019-10-31 University Of Massachusetts Artificial exosome composition and related methods
US20190365653A1 (en) 2018-06-04 2019-12-05 Korea Institute Of Science And Technology Novel recombinant exosome containing hyaluronidase and use thereof
WO2021207273A1 (en) 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1951368A (zh) * 2006-11-03 2007-04-25 李万忠 白藜芦醇口服多相脂质体及其制备方法
CN103446055A (zh) * 2013-08-22 2013-12-18 合肥工业大学 三羟基异黄酮脂质纳米体的制备方法
CN105287382A (zh) * 2015-12-10 2016-02-03 南昌大学 叶酸-壳聚糖修饰姜黄素纳米脂质体的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CEDAR ET AL.: "Ultra-flexible nanocarriers for enhanced topical delivery of a highlylipophilic antioxidative molecule for skin cancer chemoprevention", 《COLLOIDS AND SURFACES B: BIOINTERFACES》 *
ELINE ET AL.: "An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
HUANG ET AL.: "Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin", 《JOURNAL OF DRUG TARGETING》 *
邵堃等: "脑靶向药物纳米递释系统", 《东南大学学报(医学版)》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114259486A (zh) * 2020-09-16 2022-04-01 香港科技大学 木犀草素及其药物组合物的应用
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
WO2023226136A1 (zh) * 2022-05-26 2023-11-30 深圳先进技术研究院 一种用于脑部疾病诊断和治疗的微针系统及其制备方法
CN117551095A (zh) * 2023-11-09 2024-02-13 中国药科大学 一种玫瑰树碱衍生物及其制备方法与应用
CN117551095B (zh) * 2023-11-09 2025-02-07 中国药科大学 一种玫瑰树碱衍生物及其制备方法与应用

Also Published As

Publication number Publication date
EP3606557A4 (en) 2020-12-16
JP2020515638A (ja) 2020-05-28
EP3606557A1 (en) 2020-02-12
US12514929B2 (en) 2026-01-06
JP2023075276A (ja) 2023-05-30
CA3058782A1 (en) 2018-10-11
US20200030457A1 (en) 2020-01-30
WO2018187240A1 (en) 2018-10-11
JP7280624B2 (ja) 2023-05-24

Similar Documents

Publication Publication Date Title
JP7280624B2 (ja) 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル（ｄｎｖ）
Li et al. pH responsiveness of hexosomes and cubosomes for combined delivery of brucea javanica oil and doxorubicin
EP3787607B1 (en) Carotenoid compositions and uses thereof
CN103179952B (zh) 基于纳米颗粒的肿瘤靶向药物递送
JP6894423B2 (ja) 融合性リポソーム被覆多孔質ケイ素ナノ粒子
US20250295586A1 (en) Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
Gouveia et al. Non-biologic nanodelivery therapies for rheumatoid arthritis
KR20210113291A (ko) 복수의 리간드로 관능화된 폴리머좀
CN102811707A (zh) 结合生物矿物和金属的脂质体，它们的合成以及其使用方法
Salunkhe et al. Development of lipid based nanoparticulate drug delivery systems and drug carrier complexes for delivery to brain
Mutreja et al. Lipid nanoparticle-based formulations for high-performance dentistry applications
Darji et al. Recent method to improve stability profile, pharmacokinetic and pharmacodynamic properties in anticancer drugs
Chandra et al. An overview: The novel carrier for vesicular drug delivery system
Benedini et al. Nanodevices for facing new challenges of medical treatments: Stimuli-responsive drug delivery systems
CN118265543A (zh) 可用于治疗癌症的含有免疫原性细胞死亡(icd)诱导前药的经调配和/或共调配的纳米载剂组合物以及其方法
Hashim et al. Nanomaterials in chemotherapy
Yadav et al. Specialized Drug Delivery Systems
Chen et al. Nanoscale self-assembly for delivery of therapeutics and imaging agents
Alhefzi Design and Optimization of Functional Polymer-Modified Liposome Formulations for Enhanced Delivery of Therapeutics for Cancer and Depression
Bertoni et al. Exploring the Use of Spray Congealing to Produce Solid Dispersions with Enhanced Indomethacin Bioavailability
Mohammed et al. 16 Potential of Dendrimers as
Rehman An in-depth study of DOPE: DOPC liposomes to maximize targeted drug delivery to cancer-associated cells
CA3218313A1 (en) Methods and compositions for treating aging and chronic disease
Mavuso A Dermal Sludge for Targeted Genetic Auto-Inflammatory Skin Disorders
OA20783A (en) Carotenoid compositions and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200107